Sebastiano

Epigenetic Reprogramming Safe, Effective in Skin Using eTurna™ Delivery System: SEASON Conference Presentation

Retrieved on: 
Monday, June 12, 2023
Tissue, Sebastiano, RNA, Cell, Messenger, ERA, Patient, Extracellular matrix, King, ECM, LNP, Congress, King's College, Conference, Skin, Safety, Vaccine

Sebastiano was invited to be a key faculty member during the SEASON Aesthetic Conference 2023, at King's College in London on June 9-11.

Key Points: 
  • Sebastiano was invited to be a key faculty member during the SEASON Aesthetic Conference 2023, at King's College in London on June 9-11.
  • A pioneer in epigenetic reprogramming, he discussed the efficacy and safety of this therapy.
  • "Epigenetic reprogramming promises to be a powerful tool that may transform how patients are treated," Sebastiano said.
  • Turn Bio previously presented data at the SEASON Aesthetic Conference in Washington D.C. in April.

Turn Biotechnologies Founder to be Featured Speaker at Japanese Society of Anti-Aging Medicine Meeting

Retrieved on: 
Monday, June 5, 2023
Society, All Ages, Ageing, Sebastiano, Research, Messenger, Notifiable disease, Longevity, Woman, Skin, JST, Vaccine

Sebastiano, a pioneer in epigenetic reprogramming, will be the only speaker at the 23rd Annual Meeting of the Japanese Society of Anti-Aging Medicine (JAAM) representing a non-Japanese company.

Key Points: 
  • Sebastiano, a pioneer in epigenetic reprogramming, will be the only speaker at the 23rd Annual Meeting of the Japanese Society of Anti-Aging Medicine (JAAM) representing a non-Japanese company.
  • Sebastiano and his team have used Turn Bio's ERA™ technology to reprogram several cell types, including skin and immune cells.
  • "Our success in the lab shows that epigenetic reprogramming offers great promise for overcoming these currently incurable conditions."
  • The theme for this JAAM meeting is "Anti-Aging for Men and Women of All Ages – From Womb to Tomb."

T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness

Retrieved on: 
Monday, October 24, 2022
Gene expression, Administration, Time, Houston, Disease, RNA transfection, Sebastiano, Efficiency, Ophthalmology, Houston Methodist Hospital, Dermatology, Patient, ERA, RNA, Research, Tissue, Osteoarthritis, Electroporation, Technology, Cancer, CAR, New, CST, Patient safety, Safety, Epigenome, Ageing, Epigenetics, Vaccine, Pharmaceutical industry, Medical imaging

The findings promise to help reduce the cost of T-cell therapies and make them more accessible to cancer patients.

Key Points: 
  • The findings promise to help reduce the cost of T-cell therapies and make them more accessible to cancer patients.
  • "ERA provides the opportunity for enhanced dose management and optimization with the ability to personalize dosing to maximize efficiency without compromising patient safety.
  • "We found eTurna preserves T-cell health and functionality better than electroporation, facilitating greater cell viability and production during CAR T manufacturing," he said.
  • Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems.

T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness

Retrieved on: 
Monday, October 24, 2022
Gene expression, Administration, Time, Houston, Disease, RNA transfection, Sebastiano, Efficiency, Ophthalmology, Houston Methodist Hospital, Dermatology, Patient, ERA, RNA, Research, Tissue, Osteoarthritis, Electroporation, Technology, Cancer, CAR, New, CST, Patient safety, Safety, Epigenome, Ageing, Epigenetics, Vaccine, Pharmaceutical industry, Medical imaging

The findings promise to help reduce the cost of T-cell therapies and make them more accessible to cancer patients.

Key Points: 
  • The findings promise to help reduce the cost of T-cell therapies and make them more accessible to cancer patients.
  • "ERA provides the opportunity for enhanced dose management and optimization with the ability to personalize dosing to maximize efficiency without compromising patient safety.
  • "We found eTurna preserves T-cell health and functionality better than electroporation, facilitating greater cell viability and production during CAR T manufacturing," he said.
  • Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems.

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Retrieved on: 
Monday, August 8, 2022
Stanford Institutes of Medicine Summer Research Program, Dermatology, Epigenetics, CEO, American Federation for Aging Research, Gene expression, Leadership, Stanford University, Disease, Coronavirus Scientific Advisory Board (Turkey), Research, Max Planck Institute for Molecular Biomedicine, Obstetrics, Quality of life, Cell, ERA, Stanford School, Conditional sentence, Ageing, Osteoarthritis, Epigenome, Doctor of Philosophy, Glossary, University, Science, Ophthalmology, Solution, Max Planck Society, AFAR, RNA transfection, Stanford University School of Medicine, Pharmaceutical industry, Vaccine, Sebastiano

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Key Points: 
  • Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells.
  • Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.
  • A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming.
  • His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases.

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Retrieved on: 
Monday, August 8, 2022
Stanford Institutes of Medicine Summer Research Program, Dermatology, Epigenetics, CEO, American Federation for Aging Research, Gene expression, Leadership, Stanford University, Disease, Coronavirus Scientific Advisory Board (Turkey), Research, Max Planck Institute for Molecular Biomedicine, Obstetrics, Quality of life, Cell, ERA, Stanford School, Conditional sentence, Ageing, Osteoarthritis, Epigenome, Doctor of Philosophy, Glossary, University, Science, Ophthalmology, Solution, Max Planck Society, AFAR, RNA transfection, Stanford University School of Medicine, Pharmaceutical industry, Vaccine, Sebastiano

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Key Points: 
  • Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells.
  • Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.
  • A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming.
  • His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases.

Vejii Announces LOI to Acquire UK-Based Frozenly Limited Inc.

Retrieved on: 
Monday, May 9, 2022
Employment, NOAC, Social, Miray, OTC, Financial News, View, CEO, Risk, Forward-looking statement, Agriculture, Twitter, NASDAQ, Company, CSE, LOI, Woman, LinkedIn, News, Social media, THE, IPO, Intelligence, Blue Horizon, Food industry, COO, Population, Negotiation, EBITDA, Union, Letter, SPAC, Growth, Acquisition, Multimedia, United Kingdom, Venture capital financing, Data East USA, Inc. v. Epyx, Inc., Freedom, D2C, Intention, Canadian Securities Exchange, Restaurant, Retail, Security (finance), Financial services, Online shopping, Audit, Sebastiano, BC, Instagram, Facebook

Frozenly owns and operates MightyPlants.com , an e-commerce platform and marketplace that provides Direct to Consumer ("D2C") logistics and delivery for plant-based foods across the UK.

Key Points: 
  • Frozenly owns and operates MightyPlants.com , an e-commerce platform and marketplace that provides Direct to Consumer ("D2C") logistics and delivery for plant-based foods across the UK.
  • Frozenly has already established distribution in the UK market and formed relationships with top domestic and international brands.
  • Similar to Vejii's fulfilment model, Frozenly acts as an agent for brands, providing D2C order fulfilment services and sample distribution through its inventory consignment model.
  • "We are very excited to announce the signing of this LOI and the planned acquisition of Frozenly.